Drugs / MultiTAA-specific T cells
MultiTAA-specific T cells
also known as
Multiple tumor-associated antigen (TAA)-specific T cells · multiTAA T cells · TAA-CTLs · tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes
Cell therapy targets PRAME, WT1 via depletion
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02475707 | Feb 2016 → Oct 2019 | acute lymphoblastic leukemia | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02494167 | Feb 2016 → Apr 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03192462 | Jan 2018 → Jun 2020 | malignant pancreatic neoplasm | Baylor College of Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-01-03 | Marker Therapeutics, Inc. | Results Marker Therapeutics Provides Updates of its Lead Clinical Programs markertherapeutics.com ↗
while the remaining six have all had complete and durable responses (4 months to 60+ months), as assessed by PET imaging. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-01-03 | Marker Therapeutics, Inc. | Marker Therapeutics Provides Updates of its Lead Clinical Programs markertherapeutics.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MultiTAA-specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02494167 ↗ |
| Known as | Multiple tumor-associated antigen (TAA)-specific T cells | “Multiple tumor-associated antigen (TAA)-specific T cells” NCT02494167 ↗ |
| Known as | multiTAA T cells | “Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description.” NCT03192462 ↗ |
| Known as | TAA-CTLs | “These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration.” NCT03192462 ↗ |
| Known as | tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes | “Patients who have pancreatic cancer that has come back or has not gone away after treatment, including the standard treatment for this disease or patients who are not eligible...” NCT03192462 ↗ |
| Action | Deplete | “these cells will be able to recognize and kill leukemia cells that express these antigens” NCT02475707 ↗ |
| Modality | Cell therapy | “The investigators will grow T cells from patients' stem cell donors” NCT02475707 ↗ |
| Route | Intravenous | “They are administered by intravenous injection over 1-10 minutes” NCT02475707 ↗ |
| Target | PRAME | “train them to recognize the tumor proteins WT1, PRAME and Survivin” NCT02475707 ↗ |
| Target | WT1 | “train them to recognize the tumor proteins WT1, PRAME and Survivin” NCT02475707 ↗ |